Skip to main content
SCL Science Inc. logo

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 312 across all filing types
Latest filing 2026-05-15 Annual Report
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 96% confidence The document is a corrected version (정정신고) of the company’s 제16기 사업보고서, which is the comprehensive annual business report (including full financial tables, corporate overview, business description, history, governance and capital changes). It is not merely an announcement or notice but contains the full content of the company’s annual report. Therefore, it corresponds to an Annual Report. FY 2025
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is labeled as a Korean "분기보고서" (quarterly report) covering the period 2026-01-01 to 2026-03-31. It contains comprehensive financial statements, detailed company overview, subsidiary schedules, capital structure changes, and other substantive data typical of a full interim/quarterly report rather than a brief announcement. Per the definitions, this falls squarely under Interim/Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings
2026-05-07 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is titled “정기주주총회결과” (Annual General Meeting Results) and details the resolutions voted on at the AGM, including financial statement approvals, director and auditor appointments, vote counts, and percentages. It reports the official voting results for each agenda item. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement. It is not a full annual report, proxy solicitation, or management presentation but specifically a vote-results announcement for the AGM.
2026-03-31 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a regulatory disclosure titled “사외이사의 선임·해임 또는 중도퇴임에 관한 신고,” detailing the appointment and dismissal of outside directors at the company, filed with the Financial Services Commission/Korea Exchange. This is clearly an announcement of changes in the company’s board of directors, matching the Board/Management Information category.
2026-03-31 Korean
소송등의제기ㆍ신청(경영권분쟁소송) (의안상정가처분)
Legal Proceedings Report Classification · 90% confidence The document is a corporate announcement in Korean detailing the initiation and withdrawal of a lawsuit (management dispute litigation), including case title, plaintiffs, petition details, court jurisdiction, and related dates. This clearly constitutes an update on significant legal proceedings involving the company, fitting the "Legal Proceedings Report" category.
2026-03-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.